- 表现优化 -
The utilisation of engineered therapeutic proteins (recombinant proteins/recombinant antibodies) for basic research, clinical diagnostics and therapy continues to expand. Consequently, the efficient expression and production of these valuable biomolecules face challenges in improving their quantity and quality while minimising time and cost. To meet these demands, an increasing variety of recombinant production platforms called “cell factories” are being developed. Unfortunately, there is no “universal” production system which can guarantee high yields, particularly as every protein itself causes its own issues in terms of expression and production.   

Through case studies, the Optimising Expression Platforms conference offers comparisons, evaluations and solutions that enable protein engineers to efficiently express the therapeutic protein of their choice. 


Preliminary Agenda


KEYNOTE PRESENTATION: Transient Protein (Gene) Expression: From R&D towards Pharmaceutical Manufacturing
Florian M. Wurm, Dr. rer. nat., Professor Emeritus, Swiss Federal Institute of Technology Lausanne (EPFL); Founder, Chairman, ExcellGene SA

ANTIBODY EXPRESSION

Discovery of Novel Enhancers for Antibody Expression by Transcriptomics-Based Pathway Analysis
Markus Neubauer, PhD, Head, Cell Culture Research, Pharma Research & Development, Roche Innovation Center Munich

Making and Testing the Human Secretome
Rick Davies, PhD, Associate Director, Discovery Biology, AstraZeneca Pharmaceuticals

High-Throughput Antigen and Antibody Production at the IPI
James Love, PhD, COO, Institute for Protein Innovation, Harvard Institutes of Medicine

How Do We Assemble an Effective and Efficient Protein Production Toolbox?
Richard Altman, MS, Scientist, Protein Technologies, Amgen

DIFFICULT-TO-EXPRESS PROTEINS

FEATURED PRESENTATION: High-Throughput Expression and Screening of Human Integral Membrane Proteins
Nicola Burgess-Brown, PhD, Principal Investigator, Biotechnology, Structural Genomics Consortium (SGC), University of Oxford

FEATURED PRESENTATION: Engineering CHO Cells for Production of Hard-to-Produce Proteins
Bjørn Voldborg, MSc, Director, CHO Cell Line Development, The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark

Challenging Molecules in Biopharmaceutical Development: Innovative Tools for Cell Line Development
Martin Gamer, PhD, Associate Director, Early Stage Bioprocess Development, Boehringer Ingelheim Pharma GmbH & Co. KG

Sponsored Presentations

Selexis’ SUREscan and SUREsignature: Technologies for Assessment of Cell Line Integrity and Clonality
Igor Fisch, CEO, Selexis SA

Scaling Up and Scaling Out: Pushing the Boundaries of Transient Protein Production
Ian Wilkinson, CSO, Research and Development, Absolute Antibody Ltd


Luncheon Presentation I: Streamlined Discovery and Production of Therapeutic Antibodies
Meelis Kadaja, PhD, MBA, Director, Business Development, Icosagen Cell Factory


* 活动内容有可能不事先告知作更动及调整。

Choose your language
Chinese
Japanese
Korean
English